Leading the way to safer medication
 Crosscheck  Recommender

ATC Group: A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors

Anatomical Therapeutic Chemical Classification System

Hierarchical Position

Level
Code
Title
1
A
Alimentary tract and metabolism
2
A10
Drugs used in diabetes
3
A10B
Blood glucose lowering drugs, excl. insulins
4
A10BH
Dipeptidyl peptidase 4 (DPP-4) inhibitors

Contents

Code
Title
A10BH01
Sitagliptin
A10BH02
Vildagliptin
A10BH03
Saxagliptin
A10BH04
Alogliptin
A10BH05
Linagliptin
A10BH06
Gemigliptin
A10BH07
Evogliptin
A10BH08
Teneligliptin
A10BH51
Sitagliptin and simvastatin
A10BH52
Gemigliptin and rosuvastatin

Active Ingredients

Chemical substance
Description
Alogliptin

Alogliptin is a potent and highly selective inhibitor of DPP-4, >10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9. Alogliptin improves glycaemic control via a glucose-dependent mechanism, whereby insulin release is enhanced and glucagon levels are suppressed when glucose levels are high.

Linagliptin

Linagliptin is an inhibitor of the enzyme DPP-4 (dipeptidyl peptidase 4, EC 3.4.14.5) an enzyme which is involved in the inactivation of the incretin hormones GLP-1 and GIP (glucagon-like peptide1, glucose-dependent insulinotropic polypeptide). These hormones are rapidly degraded by the enzyme DPP-4. Both incretin hormones are involved in the physiological regulation of glucose homeostasis.

Saxagliptin

Saxagliptin is a highly potent (Ki: 1.3 nM), selective, reversible, competitive, DPP4 inhibitor. Saxagliptin improves glycaemic control by reducing fasting and postprandial glucose concentrations in patients with type 2 diabetes.

Sitagliptin

Sitagliptin is a member of a class of oral anti-hyperglycaemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors. The improvement in glycaemic control observed with this medicinal product may be mediated by enhancing the levels of active incretin hormones.

Vildagliptin

Vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion by increasing the endogenous levels of these incretin hormones. The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).

Monographs

Monograph
Type
Country
JALRA Tablet
MPI, EU: SmPC
JANUVIA Film-coated tablets
MPI, EU: SmPC
NESINA Film-coated tablet
MPI, US: SPL/PLR
US
ONGLYZA Film-coated tablets
MPI, EU: SmPC
TRAJENTA Film-coated tablets
MPI, EU: SmPC
VIPIDIA Film-coated tablets
MPI, EU: SmPC